Sunday, 28 Nov, 2021


Covid vaccine 'Bangavax' approved for human trial

Staff Correspondent |
Update: 2021-11-23 19:54:33
Covid vaccine 'Bangavax' approved for human trial

The local pharmaceutical company Globe Biotech Limited has been given approval to begin human trials of Bangavax, a single-dose Covid-19 vaccine.

Bangladesh Medical Research Council (BMRC) gave the approval in principle, said a letter signed by its director Prof. Dr. Ruhul Amin on Tuesday (Nov 23). 

Earlier, Globe Biotech Limited completed trials on 56 monkeys over a period of three months.

According to the vaccine developers, Bangavax does not have any side effects. They obtained a 95% success rate conducting trials on monkeys. The success rate will only vary by about 2%, in human trials, they hoped. 

In July last year, Globe Biotech announced that it was developing a Covid-19 vaccine.

On December 28, 2020, the DGDA gave permission to the pharmaceutical company to manufacture its Covid-19 vaccine for clinical trials. 

Globe Biotech approached the DGDA on January 15 this year, seeking permission for clinical trials.

BDST: 1754 HRS, NOV 23, 2021

All rights reserved. Sale, redistribution or reproduction of information/photos/illustrations/video/audio contents on this website in any form without prior permission from are strictly prohibited and liable to legal action.